Compare · MDT vs MOVE
MDT vs MOVE
Side-by-side comparison of Medtronic plc. (MDT) and Corvex Inc. (MOVE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDT and MOVE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $116.66B, about 454.2x MOVE ($256.8M).
- MDT has been more active in the news (14 items in the past 4 weeks vs 5 for MOVE).
- MDT has more recent analyst coverage (25 ratings vs 0 for MOVE).
- Company
- Medtronic plc.
- Corvex Inc.
- Price
- -
- -
- Market cap
- $116.66B
- $256.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 14
- 5
- Recent ratings
- 25
- 0
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Corvex Inc.
Movano Inc., a technology company, develops a smart wearable and continuous glucose monitoring device. Its device enables individuals and their healthcare partners to measure and manage their health conditions. Movano Inc. was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. The company was incorporated in 2018 and is based in Pleasanton, California.
Latest MDT
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 1,084 units of Ordinary Shares, decreasing direct ownership by 0.92% to 116,336 units (SEC Form 4)
- Medtronic announces cash dividend for second quarter of fiscal year 2027
- SEC Form DEFA14A filed by Medtronic plc.
- SEC Form DEF 14A filed by Medtronic plc.
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 212 units of Ordinary Shares and was granted 2,337 units of Ordinary Shares, increasing direct ownership by 14% to 16,998 units (SEC Form 4)
- EVP & President, Neuroscience Thompson Kweli covered exercise/tax liability with 1,739 units of Ordinary Shares and was granted 6,923 units of Ordinary Shares, increasing direct ownership by 17% to 35,390 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 1,675 units of Ordinary Shares and was granted 5,769 units of Ordinary Shares, increasing direct ownership by 11% to 39,928 units (SEC Form 4)
- EVP, GC and Secretary Quinn Michelle was granted 6,346 units of Ordinary Shares, increasing direct ownership by 31% to 26,721 units (SEC Form 4)
Latest MOVE
- Corvex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Corvex Inc.
- Corvex Reports Second Quarter 2026 Results and Provides Business Update
- Corvex to Host Second Quarter 2026 Earnings Call on Friday, August 14, 2026
- Corvex Signs Multi-Year Agreement to Provide NVIDIA Blackwell GPUs
- SEC Form EFFECT filed by Corvex Inc.
- SEC Form 424B7 filed by Corvex Inc.
- Corvex Appoints AI Infrastructure Veteran Michael Craig as Vice President of Architecture and Site Operations
- SEC Form S-1 filed by Corvex Inc.
- Co-Chief Executive Officer Demsey Seth converted options into 5,515,658 shares, increasing direct ownership by 178% to 8,563,155 units (SEC Form 4)